{"id":"rotateq","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"}]},"_chembl":null,"_dailymed":{"setId":"aaf3b24e-85fd-43ee-b657-2ee4df312ec3","title":"ROTATEQ (ROTAVIRUS VACCINE, LIVE, ORAL, PENTAVALENT) SOLUTION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RotaTeq contains five live reassortant rotavirus strains (bovine-human hybrids) that replicate in the intestinal tract and trigger both humoral and cell-mediated immune responses. The vaccine prevents rotavirus gastroenteritis by inducing protective antibodies and T-cell responses that recognize and neutralize wild-type rotavirus upon natural exposure.","oneSentence":"RotaTeq is a live attenuated rotavirus vaccine that stimulates the immune system to produce antibodies and cellular immunity against rotavirus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:18.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of rotavirus gastroenteritis in infants and young children"}]},"trialDetails":[{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT00880698","phase":"PHASE2","title":"Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"HIV Infection, Rotavirus Infection","enrollment":202},{"nctId":"NCT01026779","phase":"","title":"Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island","status":"COMPLETED","sponsor":"Lifespan","startDate":"2009-07","conditions":"Rotavirus Gastroenteritis","enrollment":803},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT00875641","phase":"","title":"Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-20","conditions":"Infections, Rotavirus","enrollment":390659},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT02062385","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-30","conditions":"Rotavirus Gastroenteritis","enrollment":4040},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01926015","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-19","conditions":"Rotavirus Disease","enrollment":192},{"nctId":"NCT01600092","phase":"PHASE3","title":"A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-04-29","conditions":"Rotavirus Gastroenteritis","enrollment":1020},{"nctId":"NCT02193061","phase":"PHASE3","title":"Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs","status":"COMPLETED","sponsor":"National Institute of Pediatrics, Mexico","startDate":"2013-11","conditions":"Rotavirus Vaccine","enrollment":1498},{"nctId":"NCT02847026","phase":"PHASE4","title":"Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-09","conditions":"Poliomyelitis","enrollment":1144},{"nctId":"NCT02542462","phase":"PHASE4","title":"Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-11","conditions":"Intussusception, Rotavirus Infections","enrollment":144},{"nctId":"NCT00443846","phase":"PHASE3","title":"RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-13","conditions":"Meningitis, Meningococcal, Rotavirus Infections","enrollment":247},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT02728869","phase":"PHASE1, PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants","status":"COMPLETED","sponsor":"MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.","startDate":"2016-06","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT01236066","phase":"","title":"Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Rotavirus Gastroenteritis, Gastroenteritis","enrollment":1},{"nctId":"NCT01960725","phase":"PHASE4","title":"An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)","status":"COMPLETED","sponsor":"Dennis Clements","startDate":"2014-02","conditions":"Diarrhea, Gastroenteritis","enrollment":66},{"nctId":"NCT00718237","phase":"PHASE3","title":"Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Rotavirus, Gastroenteritis","enrollment":762},{"nctId":"NCT00496054","phase":"PHASE3","title":"Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Gastroenteritis, Rotavirus","enrollment":110},{"nctId":"NCT01074242","phase":"","title":"ROTATEQ Reexamination Study (V260-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Gastroenteritis Rotavirus","enrollment":3798},{"nctId":"NCT00362648","phase":"PHASE3","title":"Developing World Study for RotaTeq™ (V260-015)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03","conditions":"Vomiting, Diarrhea, Fever","enrollment":7504},{"nctId":"NCT00953056","phase":"PHASE1","title":"A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Rotavirus Gastroenteritis","enrollment":144},{"nctId":"NCT01357174","phase":"","title":"ROTATEQ™ Post-Marketing Surveillance in the Philippines","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Rotavirus Infections, Gastroenteritis","enrollment":915},{"nctId":"NCT01003431","phase":"PHASE3","title":"A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12","conditions":"Rotavirus Gastroenteritis, Diphtheria, Tetanus","enrollment":""},{"nctId":"NCT00258154","phase":"PHASE3","title":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Rotavirus Disease","enrollment":403},{"nctId":"NCT00092456","phase":"PHASE3","title":"Consistency Lots Vaccine Study (V260-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-05","conditions":"Rotavirus Infections","enrollment":793},{"nctId":"NCT00090233","phase":"PHASE3","title":"Rotavirus Efficacy and Safety Trial (REST)(V260-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-01","conditions":"Rotavirus Infections","enrollment":69274},{"nctId":"NCT00092443","phase":"PHASE3","title":"Dose Confirmation Efficacy Study (V260-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09","conditions":"Rotavirus Infections","enrollment":1312},{"nctId":"NCT00836498","phase":"PHASE1","title":"A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Rotavirus","enrollment":66},{"nctId":"NCT00166517","phase":"PHASE3","title":"V260 Registration Study (V260-013)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Rotavirus","enrollment":178},{"nctId":"NCT00130832","phase":"PHASE3","title":"Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Rotavirus Infections, Gastroenteritis","enrollment":735},{"nctId":"NCT01266850","phase":"PHASE4","title":"Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03","conditions":"Rotavirus Infection","enrollment":1384},{"nctId":"NCT01682005","phase":"","title":"Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08","conditions":"Infections, Rotavirus","enrollment":1},{"nctId":"NCT00767364","phase":"PHASE1","title":"Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Michigan","startDate":"2009-07","conditions":"Short Bowel Syndrome","enrollment":8},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT00740935","phase":"PHASE4","title":"Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2007-05","conditions":"Rotavirus Gastroenteritis","enrollment":7204}],"_emaApprovals":[],"_faersSignals":[{"count":20,"reaction":"PYREXIA"},{"count":17,"reaction":"NO ADVERSE EVENT"},{"count":14,"reaction":"PRODUCT STORAGE ERROR"},{"count":11,"reaction":"DIARRHOEA"},{"count":8,"reaction":"DECREASED APPETITE"},{"count":7,"reaction":"ACUTE PULMONARY OEDEMA"},{"count":7,"reaction":"CARDIO-RESPIRATORY ARREST"},{"count":7,"reaction":"PAIN IN EXTREMITY"},{"count":7,"reaction":"SUDDEN DEATH"},{"count":6,"reaction":"DYSPNOEA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["V260; trade names of the concomitant vaccines may vary depending on where clinical supplies are sourced.","V260","RotaTeq™","Human-bovine rotavirus reassortants (live) vaccine","RotaTeq®"],"phase":"marketed","status":"active","brandName":"RotaTeq","genericName":"RotaTeq","companyName":"National Institute of Pediatrics, Mexico","companyId":"national-institute-of-pediatrics-mexico","modality":"Biologic","firstApprovalDate":"","aiSummary":"RotaTeq is a live attenuated rotavirus vaccine that stimulates the immune system to produce antibodies and cellular immunity against rotavirus. Used for Prevention of rotavirus gastroenteritis in infants and young children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}